JPM 2024: 'It's Really Around Focus.' Nevro Announces Restructuring Including 5% Staff Cut

Nevro will lay off 63 people to save at least $14m a year. Most of those savings will be reinvested to cover increases in normal operating costs, merit pay increases and other expenses related to the recent acquisition of Vyrsa.

J.P. Morgan 2024
• Source: Shutterstock

[Editor’s Note: A version of this article originally appeared on Medtech Insight on 10 January. It has been updated to include comments from Nevro executives at the J.P. Morgan Health Care conference on 11 January.]

More from Business

Wired Health: ‘Early Diagnosis Often Benefits Science But Not The Patient’

 

Early diagnosis can be “detrimental” to patients, Suzanne O'Sullivan, neurologist and author of “The Age of Diagnosis,” argued at the Wired Health conference on 18 March. "You save one life from screening 2,000 women for breast cancer, but you also treat 10 women unnecessarily," she said.

LSI 2025: Intuitive Surgical CEO Gary Guthart On da Vinci 5’s Force Feedback, Digital Coaching, ION Expansion, And Robotic Surgery’s Future

 
• By 

Medtech Insight sat down with Intuitive Surgical CEO Gary Guthart at the recent LSI USA conference to discuss the full launch of the new da Vinci 5 robotic system and planned digital enhancements. Guthart also offered his views on health care interoperability, AI regulation, outpatient surgeries, autonomous robots, and how the company is harnessing technology to shape the future of robotic surgery.

Owlstone Medical Develops P.aeruginosa Breath Test For Cystic Fibrosis Patients

 

Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.

Urine Test Could Halve Number Of CT Scans For Patients With Kidney Cancer

 

The urine-based GAGome test showed promise in the first clinical results from the international AURORAX-0087A, in the largest study conducted on clear cell renal cell carcinoma, the most common type of kidney cancer.

More from Conferences

Wired Health: One-Size-Fits-All Wearables Don’t Work For Women’s Health

 

Wearable technology must address women’s unique needs, said Anja Streicher, Women of Wearables chief marketing officer. Samphire Neuroscience and Amira Health demo wearable solutions for PMS and hot flashes at Wired Health.

US FDA Teleconferences In As IMDRF Gathers In Tokyo

 
• By 

The International Medical Device Regulators Forum discussed AI regulation, the development of a reliance playbook, and post-market regulation at the group's annual meeting in Tokyo last week. While the US FDA was not on-site, the agency was able to participate virtually.

Nuralogix Launches ‘Next-Generation’ MagicMirror With 4G Connectivity

 

Contactless health monitoring company Nuralogix has launched the new 4G connected Anura MagicMirror, which analyzes facial blood flow to provide health data, such as risk of heart attack, in real time.